Anavo Therapeutics BV
Joe Lewis has a diverse work experience spanning several companies and roles. Joe started their career as a Postdoc at EMBL in 1991 and later became a Group Leader at the University of Edinburgh in 1996. In 2001, they joined Anadys Pharmaceuticals as a Group Leader before moving on to become the CEO of Elara Pharmaceuticals GmbH in 2007. Joe served in this role until 2013. From 2004 to 2021, Joe was the Head of Chemical Biology Core Facility at EMBL. Currently, they are the SVP Biology and Site Head Heidelberg at Anavo Therapeutics BV, a position they have held since October 2021.
Joe Lewis has a comprehensive education history. In 1983, they attained a Bachelor of Science degree with Honors in Genetics from The University of Edinburgh. Following this, from 1987 to 1991, they pursued a Ph.D. in Biochemistry at the Institute of Molecular Pathology. Lastly, in the year 2007 to 2008, Joe attended the Mannheim Business School, where they completed a Master of Business Administration (MBA) with a focus on Business.
This person is not in any offices
Anavo Therapeutics BV
Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavois developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications